HSPA5 and plasma cell myeloma: The favourable toxicity profiles of PAT-SM6 combined with its high avidity binding to the target GRP78 and its interaction with host immune effectors form the basis for a phase I multi-dose escalating study in patients with relapsed multiple myeloma.